BPLPHARMA1,560.00

Bharat Parenterals Limited

· Pharma & Health
₹ CrorePeersJENBURPHKPLMAKERSLNOVARTINDPARNAXLABSGRLSHUKRAPHARSUNLOC
View
In ₹ Crore except Per Share
12 Months Ending
FY22
31/03/2022
FY23
31/03/2023
Adjustments to Reconcile Profit — Non-cash Items
+ Depreciation & Amortisation5.8
+ Finance Costs2.2
+ Interest Income-1.8
Changes in Working Capital
+ Inventories-17.1
+ Trade Receivables — Current-39.1
+ Trade Payables — Current25.4
Cash from Operating Activities
Profit Before Tax (per I/S)28.432.2
Cash from Operations (pre-tax)-2.8
+ Income Taxes Paid8.8
Cash from Operating Activities-11.6
Cash from Investing Activities
+ Interest Received — Investing2.8
Cash from Investing Activities21.8-13.9
Cash from Financing Activities
+ Proceeds from Borrowings3.70.0
+ Repayment of Borrowings2.52.5
Cash from Financing Activities2.328.5
Net Changes in Cash1.93.0
Closing Cash3.36.3
Reference Items
EBITDA28.121.4
EBITDA Margin %13.289.80
Free Cash Flow (CFO − Capex)-11.6
Cash Flow to Net Income-0.48
Cash Paid for Taxes8.8
As filed, sign as filed: a payment tagged as a positive magnitude in the filing stays positive here, so read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown — depth follows the filer, so a thin statement means a thin filing. Total Adjustments is the filer's own grand total of the reconciliation and spans BOTH the non-cash items and the working-capital block; Profit Before Tax plus it equals Cash from Operations (pre-tax). It can be reported when its components are not, so it is never a sum of the rows above it. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY23 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 85%.